Clinical Trials Browser

OTHER × Advanced Non-squamous Non-small-cell Lung Cancer × pembrolizumab × Clear all

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Phase 2 Not yet recruiting

Advanced Non-squamous Non-small-cell Lung Cancer